New #JITC article: "Correlation between recognition of autologous tumor organoids by tumor-infiltrating lymphocytes from metastatic epithelial cancers and clinical response" https://t.co/iOED3XEoco
@nicholasklemen@slgoff_SB
One third of identified drivers are non-canonical!
HLA LOH seen in many hot spot loci —> informs immunotherapy response and TCR based treatment eligibility 🧬
For breast cancer, alternative medicine alone was linked to a 267% higher mortality hazard.
Even when combined with standard treatment, mortality hazard was still 45% higher.
Modern oncology saves lives. Please consider using it.
6 yrs ago I opened my match email and was disappointed.
I made the best of it creating lifelong friends, spent time at NCI, and eventually switched residencies. Success isn’t always linear, but I’m so incredibly happy where I am today. Things have a way of working out. #match2026
At #SSO2026, @AlexGustafsonMD shares research showing that testing a patient’s immune cells against tumor organoids, or lab-grown versions of their own tumor, may help predict patient response to TIL therapy. @SocSurgOnc@OncoAlert@SmilowCancer
Dr. Nicole Aguirre presents research findings on characterizing germline variants in peritoneal surface malignancies (PSM) of appendiceal origin during a #SSO2026 poster session today at 3pm MST.
@SmilowCancer@YaleGICancers@SocSurgOnc
In a phase 1 study of the oral p53 reactivator rezatapopt in heavily pretreated patients with TP53 Y220C–mutated solid tumors, the most common adverse events were nausea and vomiting, and the overall response was 20%. Full PYNNACLE study results: https://t.co/LBqROGlouc
Science behind the Study: Restoring Function to a Variant of p53 in Solid Tumors https://t.co/5Ox6Kuax6Q
3: This roadmap highlights next-gen constructs:
Armored CAR & TCR cells
Bispecific & trispecific antibodies
Immune-stimulatory antibody conjugates (ISACs)
In vivo gene editing
AI-driven engineering
It’s a blueprint for transformative cures.
Adoptive Cell Transfer of Tumor-Infiltrating Lymphocytes for Metastatic Acral Lentiginous Melanoma. Co-authored by @AlexGustafsonMD and @nicholasklemen.
Read full article. https://t.co/TfPrvmWlRc
In a phase 2 trial, patients with metastatic, treatment-refractory #gastrointestinal cancers responded to neoantigen-reactive tumor-infiltrating #lymphocytes, not bulk ones, showing promise for refined immune cell therapy. #ImmuneTherapy#Neoantigens
https://t.co/8bSOrM3mf9
Funding from the @NIH contributed to the development of 354 out of 356 (99.4%) of the new drugs approved by the FDA between 2010 and 2019, and 🚨 100% 🚨 of FDA approved drugs btw 2010-2016. @NIH funding is the backbone of American biomedical innovation. #protecttheNIH
@HHSGov@SecKennedy How do you propose “doing really good unimpeded science” if you’ve blocked funding to the federal agencies and prohibited communication with the public? @SecKennedy@realDonaldTrump
About a month after Donald Trump took office as the 47th US president, almost all grant-review meetings remain suspended at the US National Institutes of Health (NIH), preventing the world’s largest public funder of biomedical research from spending much of its US$47 billion annual budget.
https://t.co/ly8mKijdtQ
A little bit of #SITC24. On the tail end of four days in Houston. @NCI_CCR_SB #TIL for melanoma and more! Photo courtesy of the long arms of @adinerman1990@AlexGustafsonMD